What can be co-administered with subcutaneous (SQ) devices to improve medication absorption?

Co-administering hyaluronidase with subcutaneous devices can enhance the absorption of medications by breaking down hyaluronic acid in the extracellular matrix. This enzymatic action allows for increased permeability of tissues, leading to a faster and more efficient diffusion of drugs administered through the subcutaneous route. Hyaluronidase effectively creates more space within the tissue, thereby facilitating drug delivery and improving therapeutic outcomes, especially for medications that otherwise might have limited absorption due to the viscosity of the surrounding structure.

The other options do not serve this specific purpose in relation to improving medication absorption when used with subcutaneous devices. For instance, while adrenaline can enhance certain effects of medications or help manage specific clinical situations, it does not directly improve drug absorption from subcutaneous sites. Dexamethasone is a corticosteroid that may reduce inflammation but does not contribute to enhancing absorption in the way that hyaluronidase does. Metoprolol is a beta-blocker used for cardiovascular conditions and does not have a role in facilitating the absorption of medications administered subcutaneously.